NCT03754049 - A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

November 7, 2023

Study Completion Date

November 7, 2023

Conditions

Osteoarthritis of the Knee

Interventions

DRUG

TLC599

TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).

DRUG

DSP

Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.

Trial Locations (10)

114

Tri-Service General Hospital, Taipei

116

Taipei Municipal Wanfang Hospital, Taipei

404

China Medical University Hospital, Taichung

29406

Clinical Trials of South Carolina, Charleston

33014

Panax Clinical Research, Miami

33136

South Coast Research Center, Miami

Syneos Health, Miami

78501

Futuro Clinical Trials, LLC., McAllen

84107

JBR Clinical Research, Salt Lake City

85053

Arizona Research Center, Phoenix